| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Cdk1/2 Inhibitor III targets cyclin-dependent kinase 1 (CDK1) and cyclin-dependent kinase 2 (CDK2), key regulators of the cell cycle. By inhibiting these kinases, the compound disrupts cell cycle progression, leading to antiproliferative effects. The compound is a selective CDK1/2 inhibitor. It has a molecular formula of C15H13F2N7O2S2 and a molecular weight of 425.44.
|
|---|---|
| ln Vitro |
Weak CDK1 and cell anti-proliferative efficacy is exhibited by Cdk1/2 Inhibitor III [1].
Cdk1/2 Inhibitor III exhibits potent inhibition of CDK1 and CDK2, with IC50 values in the nanomolar to micromolar range depending on the assay. It possesses cellular antiproliferative properties. The compound has shown promising results in preclinical studies as a potential anticancer agent. Its activity is consistent with its mechanism of inhibiting cell cycle progression. |
| ln Vivo |
Specific in vivo activity data for Cdk1/2 Inhibitor III is not extensively detailed in the available literature. As a potential anticancer agent, it would be evaluated in animal models of cancer to assess its antitumor efficacy and pharmacokinetic properties. The compound's in vitro antiproliferative activity suggests potential for in vivo efficacy.
|
| Enzyme Assay |
Cdk1/2 Inhibitor III's activity as a CDK1/2 inhibitor is assessed using in vitro kinase assays. These assays measure the compound's ability to inhibit the phosphorylation activity of CDK1/cyclin B and CDK2/cyclin A. IC50 values are determined from dose-response curves. Selectivity profiling against other kinases is performed to evaluate its specificity.
|
| Cell Assay |
Cellular assays for Cdk1/2 Inhibitor III involve treating cancer cell lines with the compound and measuring cell proliferation and viability. The compound's ability to induce cell cycle arrest is assessed using flow cytometry. Its effects on CDK1 and CDK2 activity in cells can be evaluated by measuring the phosphorylation of their substrates.
|
| Animal Protocol |
In vivo animal model protocols for Cdk1/2 Inhibitor III would involve its administration to tumor-bearing mice to evaluate its antitumor efficacy. The compound's effects on tumor growth, cell cycle progression, and survival would be assessed. Pharmacokinetic studies would evaluate its absorption, distribution, metabolism, and excretion.
|
| ADME/Pharmacokinetics |
Cdk1/2 Inhibitor III has a molecular weight of 425.44 and a molecular formula of C15H13F2N7O2S2. Specific pharmacokinetic data is not extensively detailed in the available literature. As a small molecule inhibitor, its pharmacokinetic properties would need to be evaluated in preclinical studies.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Cdk1/2 Inhibitor III has not been extensively characterized. As a research compound, it is intended for research use only and not for human consumption. Standard safety assessments would be required for clinical development.
|
| References |
[1]. Lin R, et al. Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11.
|
| Additional Infomation |
CDK1/2 Inhibitor III (CAS# 443798-55-8) is a research compound used to study the role of CDK1 and CDK2 in cell cycle regulation and cancer. It is a selective CDK1/2 inhibitor with antiproliferative properties. It is not approved for clinical use and is supplied as a research chemical.
|
| Molecular Formula |
C12H10N2O3
|
|---|---|
| Molecular Weight |
230.219
|
| Exact Mass |
425.054
|
| CAS # |
443798-55-8
|
| PubChem CID |
5330812
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.779
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
647
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1=CC=C(/N=N/C2=CC=CC=C2O)C(O)=C1
|
| InChi Key |
ARIOBGGRZJITQX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H13F2N7O2S2/c16-10-2-1-3-11(17)12(10)21-15(27)24-13(18)22-14(23-24)20-8-4-6-9(7-5-8)28(19,25)26/h1-7H,(H,21,27)(H2,19,25,26)(H3,18,20,22,23)
|
| Chemical Name |
5-amino-N-(2,6-difluorophenyl)-3-(4-sulfamoylanilino)-1,2,4-triazole-1-carbothioamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3437 mL | 21.7184 mL | 43.4367 mL | |
| 5 mM | 0.8687 mL | 4.3437 mL | 8.6873 mL | |
| 10 mM | 0.4344 mL | 2.1718 mL | 4.3437 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
